American society of clinical oncology statement: Human papillomavirus vaccination for cancer prevention

Journal of Clinical Oncology

Volumn 34, Issue 15, 2016, Pages 1803-1812

  Bailey, Howard H ^a   Chuang, Linus T ^b   DuPont, Nefertiti C ^c   Eng, Cathy ^d   Foxhall, Lewis E ^d   Merrill, Janette K ^e   Wollins, Dana S ^e   Blanke, Charles D ^f  

^a UNIVERSITY OF WISCONSIN   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c Gynecologic Oncology Surgs of North Houston   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CANCER PREVENTION; DRUG EFFICACY; DRUG SAFETY; DRUG UPTAKE; HEALTH CARE PERSONNEL; HEALTH EDUCATION; HUMAN; LOWEST INCOME GROUP; MEDICAL SOCIETY; MIDDLE INCOME GROUP; PAPILLOMAVIRUS INFECTION; PATIENT EDUCATION; PRIORITY JOURNAL; SOCIAL STATUS; SOCIOECONOMICS; UNITED STATES; VACCINATION; FEMALE; IMMUNOLOGY; ONCOLOGY; PHYSICIAN ATTITUDE; UTERINE CERVICAL NEOPLASMS;

FEMALE; HUMANS; MEDICAL ONCOLOGY; PAPILLOMAVIRUS VACCINES; PHYSICIAN'S ROLE; SOCIETIES, MEDICAL; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 84969504946     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.67.2014     Document Type: Article

References (85)

1. de Martel C, Ferlay J, Franceschi S, et al: Global burden of cancers attributable to infections in 2008: A review and synthetic analysis. Lancet Oncol 13:607-615, 2012
2. Schiller JT, Lowy DR: Virus infection and human cancer: An overview, in Chang MH, Jeang K-T (eds): Viruses and Human Cancer. Heidelberg, Germany, Springer, 2014, pp 1-10
3. Kim MN, Han KH, Ahn SH: Prevention of hepatocellular carcinoma: Beyond hepatitis B vaccination. Semin Oncol 42:316-328, 2015
4. Herrero R, González P, Markowitz LE: Present status of human papillomavirus vaccine development and implementation. Lancet Oncol 16:e206-e216, 2015
5. Hopkins TG, Wood N: Female human papillomavirus (HPV) vaccination: Global uptake and the impact of attitudes. Vaccine 31:1673-1679, 2013
6. de Sanjose S, Quint WG, Alemany L, et al: Human papillomavirus genotype attribution in invasive cervical cancer: A retrospective cross-sectional worldwide study. Lancet Oncol 11:1048-1056, 2010
7. Bosch FX, de SanjoséS: Chapter 1: Human papillomavirus and cervical cancer-Burden and assessment of causality. J Natl Cancer Inst Monogr 31:3-13, 2003
8. World Health Organization: Human papillomavirus (HPV) and cervical cancer fact sheet. http://www.who.int/mediacentre/factsheets/fs380/en/
9. International Agency for Research on Cancer: Cervical cancer: Estimated incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/fact-sheets-cancer.aspx
10. Luciani S, Prieto-Lara E, Vicari A: Providing vaccines against human papillomavirus to adolescent girls in the Americas: Battling cervical cancer, improving overall health. Health Aff (Millwood) 30: 1089-1095, 2011
11. Chaturvedi AK, Engels EA, Pfeiffer RM, et al: Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 29:4294-4301, 2011
12. Gillison ML, Chaturvedi AK, Lowy DR: HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 113:3036-3046, 2008 (suppl)
13. Centers for Disease Control and Prevention: Prevention of genital HPV infection and sequelae: Report of an external consultants' meeting. http://www.cdc.gov/std/hpv/hpvsupplement99.pdf
14. Benard VB, Johnson CJ, Thompson TD, et al: Examining the association between socioeconomic status and potential human papillomavirusassociated cancers. Cancer 113:2910-2918, 2008 (suppl)
15. Howlader N, Noone AM, Krapcho M, et al (eds): SEER Cancer Statistics Review, 1975-2012. Bethesda, MD, National Cancer Institute, 2015
16. Kann L, Kinchen S, Shanklin SL, et al: Youth risk behavior surveillance: United States, 2013. MMWR Suppl 63:1-168, 2014
17. Maine D, Hurlburt S, Greeson D: Cervical cancer prevention in the 21st century: cost is not the only issue. Am J Public Health 101:1549-1555, 2011
18. Luna J, Plata M, Gonzalez M, et al: Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil- in adult women. PLoS One 8:e83431, 2013
19. Pagliusi SR, Teresa Aguado M: Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 23:569-578, 2004
20. Centers for Disease Control and Prevention: Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013: United States. MMWR Morb Mortal Wkly Rep 62:591-595, 2013
21. Centers for Disease Control and Prevention: Genital HPV infection: HPV fact sheet. http://www.cdc.gov/vaccines/vpd-vac/should-not-vacc.htm
22. Schiller JT, CastellsaguéX, Garland SM: A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 30:F123-F138, 2012 (suppl 5)
23. Joura E, Bautista O, Luxembourg A: A 9-valent HPV vaccine in women. N Engl J Med 372: 2568-2569, 2015
24. Markowitz LE, Dunne EF, Saraiya M, et al: Human papillomavirus vaccination: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 63:1-30, 2014
25. Petrosky E, Bocchini JA Jr, Hariri S, et al: Use of 9-valent human papillomavirus (HPV) vaccine: Updated HPV vaccination recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 64:300-304, 2015
26. World Health Organization: New WHO guide to prevent and control cervical cancer. http://www.who.int/mediacentre/news/releases/2014/preventingcervical- cancer/en/
27. Centers for Disease Control and Prevention: Viral hepatitis: Hepatitis B information-FAQs for the public. http://www.cdc.gov/hepatitis/hbv/bfaq.htm
28. WorldHealth Organization: HepatitisBfact sheet. http://www.who.int/mediacentre/factsheets/fs204/en/
29. Komatsu H: Hepatitis B virus: Where do we stand and what is the next step for eradication? World J Gastroenterol 20:8998-9016, 2014
30. Trépo C, Chan HL, Lok A: Hepatitis B virus infection. Lancet 384:2053-2063, 2014
31. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390, 2008
32. Kane MA: Global implementation of human papillomavirus (HPV) vaccine: Lessons from hepatitis B vaccine. Gynecol Oncol 117:S32-S35, 2010 (suppl)
33. GAVI Alliance: Delivering on the Promise. http://www.gavi.org/Library/Publications/Pledgingconference- for-immunisation/Delivering-on-thepromise/
34. Mast EE, Margolis HS, Fiore AE, et al: A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1-Immunization of infants, children, and adolescents. MMWR Recomm Rep 54:1-31, 2005
35. Centers for Disease Control and Prevention: Achievements in public health: Hepatitis B vaccination-United States, 1982-2002. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5125a3.htm
36. Centers for Disease Control and Prevention: Vaccine information statement (VIS): Hepatitis B VIS. http://www.cdc.gov/vaccines/hcp/vis/vis-statements/hep-b.html
37. Centers for Disease Control and Prevention: Viral hepatitis surveillance: United States, 2009. http://www.cdc.gov/hepatitis/statistics/2009surveillance/
38. Chang M-H, You SL, Chen CJ, et al: Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: A 20-year follow-up study. J Natl Cancer Inst 101:1348-1355, 2009
39. Hadler SC, Fuqiang C, Averhoff F, et al: The impact of hepatitis B vaccine in China and in the China GAVI Project. Vaccine 31:J66-J72, 2013 (suppl 9)
40. National Health Service: HPV vaccine. http://www.nhs.uk/Conditions/vaccinations/Pages/hpvhuman- papillomavirus-vaccine.aspx
41. Fagot J-P, Boutrelle A, Ricordeau P, et al: HPV vaccination in France: Uptake, costs and issues for the National Health Insurance. Vaccine 29: 3610-3616, 2011
42. Australian Government Department of Health: Immunise Australia Program: Human papillomavirus (HPV). http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/immunise-hpv
43. Arbyn M, Simoens C, Van Damme P, et al: Introduction of HPV vaccination in Belgium, Luxembourg and the Netherlands. Gynecol Obstet Invest 70:224-232, 2010
44. Dorleans F, Giambi C, Dematte L, et al: The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: First results of the VENICE2 2010 survey. Euro Surveill 15:1-4, 2010
45. Villa L: HPV vaccines in Brazil and the world. BMC Proc 8:O7, 2014 (suppl 4)
46. International Centre for Reproductive Health: Cervical cancer prevention in Kenya: Introduction of the HPV vaccines. http://icrhb.org/project/cervicalcancer- prevention-kenya-introduction-hpv-vaccines
47. Centers for Disease Control and Prevention: Progress toward implementation of human papillomavirus vaccination-the Americas, 2006-2010. MMWR Morb Mortal Wkly Rep 60:1382-1384, 2011
48. Ali H, Donovan B, Wand H, et al: Genital warts in young Australians five years into national human papillomavirus vaccination programme: National surveillance data. BMJ 346:f2032, 2013
49. Drolet M, Bénard É, Boily MC, et al: Population-level impact and herd effects following human papillomavirus vaccination programmes: A systematic review and meta-analysis. Lancet Infect Dis 15:565-580, 2015
50. Binagwaho A, Wagner CM, Gatera M, et al: Achieving high coverage in Rwanda's national human papillomavirus vaccination programme. Bull World Health Organ 90:623-628, 2012
51. Ladner J, Besson MH, Hampshire R, et al: Assessment of eight HPV vaccination programs implemented in lowest income countries. BMC Public Health 12:370, 2012
52. Centers for Disease Control and Prevention: National and state vaccination coverage among adolescents aged 13-17 years: United States, 2012. MMWR Morb Mortal Wkly Rep 62:685-693, 2013
53. Salit R: HPV vaccination rate for R.I. seventh graders "extremely encouraging". Providence Journal, November 19, 2015. http://www.providencejournal.com/article/20151119/NEWS/151119182/?Start=2
54. Miller MK, Wickliffe J, Jahnke S, et al: Views on human papillomavirus vaccination: A mixedmethods study of urban youth. J Community Health 39:835-841, 2014
55. Office of Disease Prevention and Health Promotion: Healthy People 2020: HPV vaccine, adolescents, 2008-2012. https://www.healthypeople.gov/2020/topics-objectives/national-snapshot/hpv-vaccineadolescents- 2008%E2%80%932012
56. Reagan-Steiner S, Yankey D, Jeyarajah J, et al: National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years: United States, 2014.MMWR MorbMortalWkly Rep 64:784-792, 2015
57. Nodulman JA, Starling R, Kong AS, et al: Investigating stakeholder attitudes and opinions on school-based human papillomavirus vaccination programs. J Sch Health 85:289-298, 2015
58. President's Cancer Panel: Annual report 2012-2013: Accelerating HPV vaccine uptake: Urgency for action to prevent cancer. http://deainfo.nci.nih.gov/advisory/pcp/annualReports/HPV/
59. Schluterman NH, Terplan M, Lydecker AD, et al: Human papillomavirus (HPV) vaccine uptake and completion at an urban hospital. Vaccine 29: 3767-3772, 2011
60. Tan W, Viera AJ, Rowe-West B, et al: The HPV vaccine: are dosing recommendations being followed? Vaccine 29:2548-2554, 2011
61. Rubin RF, Kuttab HM, Rihani RS, et al: Patient adherence to three dose completion of the quadrivalent human papillomavirus (HPV) vaccine in a private practice. J Community Health 37:1145-1150, 2012
62. Lechuga J, Vera-Cala L, Martinez-Donate A: HPV vaccine awareness, barriers, intentions, and uptake in Latina women. J Immigr Minor Health 18: 173-178, 2016
63. Ferrer HB, Trotter C, Hickman M, et al: Barriers and facilitators to HPV vaccination of young women in high-income countries: A qualitative systematic review and evidence synthesis. BMC Public Health 14:700, 2014
64. Donahue K, Stupiansky N, Cox A, et al: IUPUI Center for HPV Research: Effects of a brief health messaging intervention on HPV vaccine acceptability among parents of adolescent sons. http://research.iupui.edu/events/researchday2014/documents/b38.pdf
65. Hanson CM, Eckert L, Bloem P, et al: Gavi HPV programs: Application to implementation. Vaccines (Basel) 3:408-419, 2015
66. Berenson AB: An update on barriers to adolescent human papillomavirus vaccination in the USA. Expert Rev Vaccines 14:1377-1384, 2015
67. Bruno DM, Wilson TE, Gany F, et al: Identifying human papillomavirus vaccination practices among primary care providers of minority, lowincome and immigrant patient populations. Vaccine 32:4149-4154, 2014
68. Agosti JM, Goldie SJ: Introducing HPV vaccine in developing countries: Key challenges and issues. N Engl J Med 356:1908-1910, 2007
69. GAVI injects new life into HPV vaccine rollout. Lancet 381:1688, 2013
70. GAVI: Human papillomavirus vaccine support. http://www.gavi.org/support/nvs/human-papillomavirusvaccine- support/
71. GAVI: Countries approved for support. http://www.gavi.org/results/countries-approved-for-support/
72. Pan American Health Organization: Vaccine revolving fund may expand to Africa, Eastern Mediterranean regions. http://www.paho.org/hq/index.php?option5 com-content&id51553&Itemid51926&lang5en
73. Almonte M, Albero G, Molano M, et al: Risk factors for human papillomavirus exposure and co-factors for cervical cancer in Latin America and the Caribbean. Vaccine 26:L16-L36, 2008 (suppl 11)
74. Gilmer LS: Human papillomavirus vaccine update. Prim Care 42:17-32, 2015
75. O'Leary ST, Allison MA, Lindley MC, et al: Vaccine financing from the perspective of primary care physicians. Pediatrics 133:367-374, 2014
76. Rosenthal SL, Weiss TW, Zimet GD, et al: Predictors of HPV vaccine uptake among women aged 19-26: Importance of a physician's recommendation. Vaccine 29:890-895, 2011
77. Dorton BJ, Vitonis AF, Feldman S: Comparing cervical cytology and histology among human papillomavirus-vaccinated and -unvaccinated women in an academic colposcopy clinic. Obstet Gynecol 126:785-791, 2015
78. Dobson SR, McNeil S, Dionne M, et al: Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: A randomized clinical trial. JAMA 309:1793-1802, 2013
79. Bednarczyk RA, Davis R, Ault K, et al: Sexual activity-related outcomes after human papillomavirus vaccination of 11- to 12-year-olds. Pediatrics 130: 798-805, 2012
80. Schilling A, Parra MM, Gutierrez M, et al: Coadministration of a 9-valent human papillomavirus vaccine with meningococcal and Tdap vaccines. Pediatrics 136:e563-e572, 2015
81. Paul P, Fabio A: Literature review of HPV vaccine delivery strategies: Considerations for school- and non-school based immunization program. Vaccine 32: 320-326, 2014
82. Dorell C, Yankey D, Kennedy A, et al: Factors that influence parental vaccination decisions for adolescents, 13 to 17 years old: National Immunization Survey-Teen, 2010. Clin Pediatr (Phila) 52:162-170, 2013
83. Center to Reduce Cancer Health Disparities: Excess cervical cancer mortality: A marker for low access to health care in poor communities. http://www.cancer.gov/about-nci/organization/crchd/abouthealth- disparities/resources/excess-cervical-cancermortality.pdf
84. National Cancer Institute: Human papillomavirus (HPV) vaccines. http://www.cancer.gov/about-cancer/causes-prevention/risk/infectiousagents/hpv-vaccine-fact-sheet
85. President's Cancer Panel: Accelerating HPV vaccine uptake: Urgency for action to prevent cancer-HPV vaccines prevent cancer: Why are so few US adolescents vaccinated? http://deainfo.nci.nih.gov/advisory/pcp/annualReports/HPV/PDF/PCP-Annual- Report-2012-2013.pdf